KNX In Depth's Charles Feldman and Rob Archer discuss a new Alzheimer's drug. The FDA has just approved a drug that might slow the pace of cognitive decline early in the disease. But it does come with risks. With us now is April Thames, Director of the UCLA Social Neuroscience and Health Psychology Lab. She's a past Alzheimer's Association Board Member.

<p>KNX In Depth's Charles Feldman and Rob Archer discuss a new Alzheimer's drug. The FDA has just approved a drug that might slow the pace of cognitive decline early in the disease. But it does come with risks. With us now is April Thames, Director of the UCLA Social Neuroscience and Health Psychology Lab. She's a past Alzheimer's Association Board Member.</p>

Advertisement